RxDoctor Payments Data

Olivia Mechanic, MD

Cardiovascular Disease · Miami Beach, FLNPI 1285046748

Payments from drug & device makers

$2,603in general payments, 2019–2025

Across 112 payments — averaging $23.24 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novartis$316
  • Novo Nordisk$294
  • Pfizer$280
  • Boston Scientific$251
  • Amgen$211
  • Johnson & Johnson$131
  • plus $1K from 21 others

What the payments were for

  • Food & beverage$2,57199%
  • Education$321%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$2,603 in reported general payments places this provider in the 40th percentile of 1,740 cardiovascular disease providers in Florida.

See all cardiovascular disease providers in Florida

Medicare billing

Part B allowed, 2024
$83,415
Medicare patients
295
Services billed
993

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban52$67,989
EntrestoSacubitril/Valsartan42$66,418
XareltoRivaroxaban34$38,165
Repatha SureclickEvolocumab24$28,651
JardianceEmpagliflozin16$27,658
Repatha PushtronexEvolocumab27$23,529
MounjaroTirzepatide19$19,134
OzempicSemaglutide12$15,441
FarxigaDapagliflozin Propanediol15$12,408
Rosuvastatin Calcium116$2,170
Ezetimibe30$927
Metoprolol Succinate70$886
Losartan Potassium52$593
Pantoprazole Sodium37$581
Atorvastatin Calcium76$550

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$280$67,98952 claims
NovartisEntresto$316$66,41842 claims
Johnson & JohnsonXarelto$131$38,16534 claims
Lilly USA, LLCMounjaro$52$19,13419 claims
Novo NordiskOzempic$294$15,44112 claims
AstraZenecaFarxiga$84$12,40815 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 40th percentile of 1,740 cardiovascular disease providers in Florida.

Other cardiovascular disease in Miami Beach

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →